From the UCL Queen Square Institute of Neurology (S.Z., S.K., L.H.-H., H.M.C., S.M.S.), London; Chalfont Centre for Epilepsy (S.Z., S.K., H.M.C., S.M.S.), Buckinghamshire; Department of Neurology (D.S., A.V., J.H.C., M.A.K.), Great Ormond Street Hospital; Clinical Neurosciences (A.V., J.H.C.), and Neurogenetics Group (D.S., M.A.K.), Developmental Neurosciences NIHR BRC UCL Great Ormond Street Institute of Child Health, London; School of Life Sciences (S.K.), Faculty of Science and Engineering, Anglia Ruskin University, Cambridge, UK; Department of Neurology and Clinical Neurophysiology (K.M.G., M.D.K., B.J.L.), Children's Health Ireland at Temple Street, Dublin 1; School of Medicine and Medical Sciences (K.M.G., M.D.K.), University College Dublin, Dublin 4, Ireland; Danish Epilepsy Centre (R.S.M., T.B.H.), Dianalund; Department of Regional Health Research (R.S.M.), University of Southern Denmark, Odense; Department of Paediatric Neurology (R.S., A.A.M., A.M.), Bristol Royal Hospital for Children, UK; Pediatric Neurology (W.F.), Department of Pediatrics, Faculty of Medicine and University Hospital Cologne, University of Cologne; Institute of Human Genetics (T.B.), University of Leipzig Medical Center, Germany; Departement de Neuropediatrie (D.D.), Centre de Référence Neurogénetique Mouvements Anormaux, Hôpital Armand Trousseau, and Department of Genetics (B.K., C.M.), La Pitié-Salpêtrière Hospital, APHP, Sorbonne University, Paris; Centre de Référence Déficiences Intellectuelles de Causes Rares (C.M.); Departement de Pediatrie (N.B.), American Memorial Hospital, CHU Reims; CReSTIC (N.B.), University of Reims Champagne-Ardennes, France; University of Bristol (A.A.M.); Department of Haematology (A.S.-J.) and Cambridge Institute for Medical Research (F.L.R.), University of Cambridge; NIHR BioResource (A.S.-J., F.L.R.), Cambridge University Hospitals NHS Foundation Trust; Paediatric Neurology (A.B.), Great North Childrens Hospital, Newcastle upon Tyne; Population Health Sciences Institute (A.B.), Newcastle University, UK; Applied & Translational Genomics Group (H.S., S.W.), VIB-Center for Molecular Neurology, University of Antwerp; and Department of Neurology (H.S., S.W.), University Hospital Antwerp, Belgium.
Neurology. 2021 Mar 16;96(11):e1539-e1550. doi: 10.1212/WNL.0000000000011543. Epub 2021 Jan 27.
To explore the phenotypic spectrum of -related disorders and specifically to determine whether patients fulfill criteria for alternating hemiplegia of childhood (AHC), we report the clinical features of 11 affected individuals.
Individuals with -related disorders were identified through a movement disorder clinic at a specialist pediatric center, with additional cases identified through collaboration with other centers internationally. Clinical data were acquired through retrospective case-note review.
Eleven affected patients were identified. All had heterozygous missense variants involving exon 9 of , confirmed as de novo in 9 cases. All had a complex motor phenotype, including at least 2 different kinds of movement disorder, e.g., ataxia and dystonia. Many patients demonstrated several features fulfilling the criteria for AHC: 10 patients had a movement disorder including paroxysmal elements, and 8 experienced hemiplegic episodes. In contrast to classic AHC, commonly caused by mutations in , these events were reported later only in mutation-positive patients from 20 months of age. Seven patients had epilepsy, but of these, 4 patients achieved seizure freedom. All patients had intellectual disability, usually moderate to severe. Other features include episodes of marked skin color change and gastrointestinal symptoms, each in 4 patients.
Although heterozygous mutations were originally described in early infantile epileptic encephalopathy type 64, our study confirms that they account for a more expansive clinical phenotype, including a complex polymorphic movement disorder with paroxysmal elements resembling AHC. testing should therefore be considered in patients with an AHC-like phenotype, particularly those negative for mutations.
探讨 - 相关障碍的表型谱,并特别确定患者是否符合交替性偏瘫的儿童(AHC)的标准,我们报告了 11 名受影响个体的临床特征。
通过专门的儿科中心的运动障碍诊所确定 - 相关障碍的个体,并通过与国际其他中心的合作确定其他病例。通过回顾性病例记录审查获取临床数据。
确定了 11 名受影响的患者。所有患者均携带涉及 - 外显子 9 的杂合错义变异,在 9 例中确认为新生。所有患者均具有复杂的运动表型,包括至少 2 种不同类型的运动障碍,例如共济失调和肌张力障碍。许多患者表现出符合 AHC 标准的多种特征:10 名患者的运动障碍包括阵发性元素,8 名患者经历偏瘫发作。与常见于 - 突变引起的经典 AHC 相反,这些事件仅在 20 个月龄时突变阳性患者中报告。7 名患者患有癫痫,但其中 4 名患者实现了无癫痫发作。所有患者均有智力残疾,通常为中度至重度。其他特征包括 4 名患者各有 4 名患者出现明显的皮肤颜色变化和胃肠道症状。
尽管杂合 - 突变最初在 64 型早发性婴儿癫痫性脑病中被描述,但我们的研究证实它们导致了更广泛的临床表型,包括类似于 AHC 的阵发性元素的复杂多态性运动障碍。因此,应考虑对具有 AHC 样表型的患者进行 检测,特别是那些 - 突变阴性的患者。